Novartis AG Stock News

Novartis (NVS) progresses with the proposed spin-off of its Sandoz arm (scheduled for early October) and invites shareholders for a meeting on the same.

Novartis (NVS) put up a strong performance year to date based on the solid performance of key drugs and encouraging pipeline progress.

AbbVie is more unstoppable than you might think. Johnson & Johnson faces some challenges but remains a solid pick for long-term investors.

Many of Novartis' top drugs saw their revenue generation grow by double digits this year. PepsiCo did not see big drops in sales volume despite increasing its prices.

Although the best dividend stocks for portfolio protection might come off as a rather boring endeavor, at the present juncture, there may be no more relevant idea for investors. Frankly, with the worl

Deal Overview On July 18, 2023, Novartis AG (NYSE: NVS, $105.01, Market Capitalization $239.

Novartis' exceptional lineup of medicines produced stellar results in Q2. The company's market-beating dividend looks to be sustainable.

After more than a decade of trading within a wide and volatile range, it looks like Novartis NYSE: NVS shares will move to a new high and sustain the move.

Novartis released its 2023 Q2 earnings this morning. The revised forecast reflects the robust demand for key products as well as the potential launch of new therapies in its pipeline.

Novartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss what's driving the company's earnings beats, the company's newest technologies, and the 'war for talent.'

Novartis (NVS) beats on earnings and sales in the second quarter and raises its annual guidance on strong momentum.

Novartis raised its guidance and announced the buybacks as the Swiss drugmaker reported second-quarter earnings, which topped Wall Street's expectations.

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street e

Bank of America kicks off a busy day of bank earnings by beating its second quarter profit forecast and retail sales are expected to increase for June. Here's what investors need to know today.

The board also endorsed plans to spin off its generic medicines unit Sandoz early in the fourth quarter, subject to shareholder approval.